... quality of life (HRQoL) in patients receiving either ribociclib plus endocrine therapy (ET) or chemotherapy with/without bevacizumab as first-line treatment of metastatic hormone receptor (HR)-positive, HER2-negative breast cancer (BC). Patients and Methods: In this randomized, phase III study (RIBBIT...

...Christian Jackisch; Athanasios Argyriadis Background: At the end of the 19th century, Sir George Thomas Beatson first discovered the positive influence of a bilateral oophorectomy on the development of breast cancer lesions in women with advanced disease. Since then, endocrine therapy has been...

... patients (34 in group A, 20 in group B, 32 in group C) were included. The most common endocrine therapy in group B was fulvestrant (40%). The major chemotherapy regimen in group C was eribulin (25%). The median OS times after stopping CDK4/6 inhibitors were 34.5 months (95% confidence interval, 17.2 to NA...

... from any ideas, methods, instructions or products referred to in the content or advertisements. 2021 Early breast cancer Neoadjuvant systemic therapy Adjuvant treatment Endocrine therapy Chemotherapy Breast surgery Axillary surgery Radiotherapy Immunotherapy Survivorship Consensus...

...Christian Felix Reibold; Wakuma Tariku; Pia Eber-Schulz; Sefonias Getachew; Adamu Addisie; Susanne Unverzagt; Andreas Wienke; Steffen Hauptmann; Claudia Wickenhauser; Martina Vetter; Ahmedin Jemal; Christoph Thomssen; Eva Johanna Kantelhardt Introduction: Endocrine therapy for breast cancer (BC...

... with a CDK4/6 inhibitor and endocrine therapy can be considered in breast cancer brain metastases. Our patient was first diagnosed with early-stage breast cancer of the left breast at the age of 59 in 2009. Breast-conserving surgery and sentinel node biopsy was performed, and the postoperative TNM...

... participants to take their medication regularly. The study population and full inclusion and exclusion criteria have been described previously [ 24, 25 ]. The primary aim of the PACT study was to investigate whether the provision of IM packages in the first year of adjuvant endocrine therapy...

... hypocellularity and pseudoblockade of the granulocyte line at the promyelocyte stage and no mature granulocytes. Tamoxifen is the main adjuvant endocrine therapy for nonmenopausal patients with hormone-sensitive breast cancer. The toxicities of tamoxifen are mainly menopausal symptoms...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2019 Early breast cancer Neoadjuvant systemic therapy Adjuvant treatment Endocrine therapy Chemotherapy Bisphosphonates Denosumab Breast...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2019 Toxicity Side effects Quality of life Endocrine therapy Chemotherapy Breast cancer Aromatase inhibitors Adjuvant treatment Almost all patients with primary breast...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2019 Advanced breast cancer Palbociclib Ribociclib Abemaciclib Cyclin-dependent kinase 4/6 Endocrine therapy Cell cycle In January 2015, striking efficacy...

...Nicolai Maass; Helmut Ostermann; Kurt Possinger; Peter Klein; Hans Tesch; Lars Mühlenhoff; Dirk Bauerschlag Background: Endocrine therapy is recommended for the treatment of postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC). Methods: ACT-FASTER was a German...

... palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-439. 8...

... subtype. For luminal tumors receiving neoadjuvant endocrine therapy, Ki67 at 2-4 weeks and the preoperative endocrine prognostic index score are the most accepted intermediate markers of efficacy, which will be validated in ongoing larger trials. In this review, we describe the different neoadjuvant...

... effect of NAC. Our findings raise renewed interest in combinatorial cytotoxic chemotherapy with concomitant or rather sequential endocrine therapy, either alone or with targeted agents. [email protected] 12 12 2017 © 2017 S. Karger GmbH, Freiburg 2017 Copyright...

... with luminal BC do not respond to endocrine therapy and many others develop endocrine resistance over time, due to the activation of escape pathways such as the PI3K/AKT/mTOR signaling. Several clinical trials have demonstrated the efficacy of mTOR and PI3K inhibitors in overcoming endocrine resistance...

... of tamoxifen or an aromatase inhibitor for all patients with HR-positive early breast cancer is considered standard; however, there are now data to support an extended approach using up to 10 years of treatment. This review will provide some historical background on endocrine therapy and summarize the key...

... for using it in order decide about chemotherapy in this population (table 2 ). Only 46% of the panelists (no 50%) believed that multigene signatures provide valuable information for decision regarding extended endocrine therapy. Although upfront AI therapy probably is already reality in many countries...

...Cornelia Liedtke; Hans-Christian Kolberg Summary Systemic therapy of metastatic breast cancer may include chemotherapy, endocrine therapy, and targeted therapies (e.g., antibody-based approaches). These agents may be employed alone or in combination based on the patient's breast cancer subtype...

.... Advanced breast cancer Palbociclib CDK4/6 Endocrine therapy Cell cycle In February 2015, the U.S. Food and Drug Administration (FDA) approved palbociclib (Ibrance®, Pfizer Deutschland GmbH, Berlin, Germany) for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human...